Deep Dive: Deep Dive Into The 2023 Biosimilars Report

Bruce Feinberg, DO, chief medical officer of Cardinal Health, talks about the research that went into compiling the 2023 Biosimilars Report, and how adalimumab biosimilars will change the way dermatologists treat patients.